OncClub

Insights and Implications of AI’s Expanding Role in Hematologic Malignancy Care: With Justin Taylor, MD

November 19th 2025

Justin Taylor, MD discusses how patients use AI to seek cancer information, its accuracy and limitations, and the implications for hematologic malignancy care.

Shailee S. Shah, MD, clinical assistant professor, neurology (MS/neuroimmunology), Northwestern University Feinberg School of Medicine

Efficacy of Immune Checkpoint Inhibition in Oncology May Translate to Neurologic Disorders: With Shailee S. Shah, MD

ByShailee S. Shah, MD

August 5th 2025

Dr Shah discusses a study of the effect of immune checkpoint inhibitors on patients with cancer and preexisting neurologic autoimmune diseases.

Branden Moriarity, PhD, associate professor, Division of Pediatric Hematology/Oncology, co-director, Center for Genome Engineering, Genome Engineering Shared Resource (GESR), member, Center for Genome Engineering, University of Minnesota, member, Stem Cell Institute, Masonic Cancer Center; Beau Webber, PhD, associate professor. Division of Pediatric Hematology/Oncology, co-director, GESR, member, Stem Cell Institute, University of Minnesota Medical School, member, Masonic Cancer Center.

CRISPR-Edited CISH Knockout TIL Therapy Paves Novel Treatment Paths in CRC: With Branden Moriarity, PhD; and Beau Webber, PhD

ByBranden Moriarity, PhD,Beau Webber, PhD

July 28th 2025

Drs Moriarity and Webber discuss a study evaluating neoantigen-reactive CISH knockout TIL therapy in patients with metastatic gastrointestinal cancers.

Jonathan M. Gerber, MD, member, faculty, Department of Medicine, New York University (NYU) Grossman School of Medicine, chief clinical officer, NYU Perlmutter Cancer Center; Shyam A. Patel, MD, PhD, associate professor, University of Massachusetts Chan Medical School, hematologist and oncologist, UMass Memorial Medical Center

IHC Testing Leads to Early Detection of TP53-Mutant AML and MDS: With Jonathan M. Gerber, MD; and Shyam A. Patel, MD, PhD

ByJonathan M. Gerber, MD,Shyam A. Patel, MD, PhD

July 16th 2025

Drs Gerber and Patel discuss a study they conducted investigating the use of IHC as a biomarker for early TP53 mutation identification in MDS and AML.

Henry M. Kuerer, MD, PhD, FACS, CMQ, professor, breast surgical oncology, The University of Texas MD Anderson Cancer Center

Biopsy-Guided Approach Enables Surgery Omission After pCR in HER2+ and Triple-Negative Breast Cancer: With Henry M. Kuerer, MD, PhD, FACS, CMQ

ByHenry M. Kuerer, MD, PhD, FACS, CMQ

July 15th 2025

Dr Kuerer discusses the potential to omit surgery in patients with HER2-positive or triple-negative breast cancer who have pCR after neoadjuvant therapy.

Jacob Moyer, BS, graduate researcher, Mayo Clinic; Mark Tyson II, MD, MPH, urologic oncologist, associate professor, urology, Mayo Clinic Alix School of Medicine

Real-World Data Support Nadofaragene Firadenovec Use in BCG-Unresponsive NMIBC: With Jacob Moyer, BS; and Mark D. Tyson, II, MD, MPH

ByJacob Moyer, BS,Mark D. Tyson, II, MD, MPH

May 1st 2025

Rachna Shroff, MD, MS, FASCO, interim clinical affairs director, associate director, Clinical Investigations, co-lead, Gastrointestinal Clinical Research Team, The University of Arizona Cancer Center; professor, Department of Medicine, chief, Division of Hematology/Oncology, medical director, Oncology Service Line, associate dean, Clinical and Translational Research, The University of Arizona College of Medicine

Triplet Chemo Trial Raises Importance of Accurately Defined Subgroups in Biliary Tract Cancer Research: With Rachna Shroff, MD, MS, FASCO

ByRachna Shroff, MD, MS, FASCO

February 24th 2025

Dr Shroff discusses the SWOG S1815 trial of nab-paclitaxel plus gemcitabine and cisplatin in patients with newly diagnosed, advanced biliary tract cancer.

Alec Watson, MD, thoracic oncology fellow, School of Medicine, Division of Medical Oncology, University of Colorado Anschutz Medical Campus

Oncogene Analysis Identifies Clinically Relevant Gene Copy Number Gain Thresholds in NSCLC: With Alec Watson, MD

ByAlec Watson, MD

January 13th 2025

Yvonne Mowery, MD, PhD, physician scientist, associate professor, radiation oncology, University of Pittsburgh Medical Center Hillman Cancer Center

Pembrolizumab Plus Preoperative Radiotherapy and Surgery Improves DFS in Soft-Tissue Sarcoma: With Yvonne Mowery, MD, PhD

ByYvonne Mowery, MD, PhD

January 7th 2025

Dr Mowery discusses the SU2C-SARC032 trial of pembrolizumab plus preoperative radiotherapy and surgery in patients with soft-tissue sarcoma.

Alex F. Herrera, MD, chief, Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation, associate medical director, Briskin Center for Clinical Research, associate professor, Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope

Explore Findings With Nivolumab Plus AVD in Advanced-Stage Classic Hodgkin Lymphoma: With Alex F. Herrera, MD

ByAlex Herrera, MD

December 13th 2024

Dr Herrera explains why N+AVD is a strong candidate for primary treatment in adolescent and adult patients with stage III or IV Hodgkin lymphoma.

Heinz-Josef Lenz, MD, FACP, about the prognostic and predictive value of HER2 gene expression for patients with KRAS wild-type metastatic colorectal cancer (mCRC). Lenz is a professor in the Department of Medicine and the Department of Preventive Medicine in the Division of Oncology at the University of Southern California (USC) Keck School of Medicine in Los Angeles. He also serves as the associate director of Clinical Research, chair of the Gastrointestinal Oncology Program, and co-director of the Colorectal Center at the USC Norris Comprehensive Cancer Center

Lenz Discusses the Prognostic and Predictive Value of HER2 Gene Expression in KRAS Wild-Type mCRC

ByHeinz-Josef Lenz, MD

June 3rd 2024

Lenz discusses the link between HER2 expression and responses with mCRC treatment regimens and how HER2 expression can guide treatment decision-making.

Amin Nassar, MD, hematology/oncology fellow, Yale University; Elias Bou Farhat, MD, postdoctoral research fellow, Department of Medicine, Brigham and Women’s Hospital

Bou Farhat and Nassar on the Use of NGS Mutation Signature vs IHC for Identifying dMMR Tumors

ByAmin Nassar, MD,Elias Bou Farhat, MD

April 29th 2024

Drs Nassar and Bou Farhat explain how tumor-only NGS could address the limitations of IHC testing for MMR mutation signatures across several tumor types.

Feigin Discusses the Association Between Benzodiazepines and Pancreatic Cancer Outcomes

ByOncLive Staff

November 13th 2023

Dr Feigin discusses findings from a study on the varying effects of the benzodiazepines lorazepam and alprazolam on progression-free survival outcomes for patients with pancreatic cancer.

King Describes Unmet Needs and the Role of Surgical Resection in Residual Non-RP Testicular Cancer

ByOncLive Staff

July 6th 2023

Dr King discusses the need for improved guidance when determining the appropriate management strategy for patients with residual nonretroperitoneal testicular cancer and findings from a study on the association between the presence of teratoma in the primary orchiectomy and the rate of teratoma in this disease.